Navigation Links
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced the results of a controlled clinical trial, published in the September 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol, a selective beta 1-blocker with vasodilating properties, significantly reduced sitting diastolic and systolic blood pressure among patients with mild-to-moderate hypertension. The study - the first to evaluate the drug in a U.S. population - also found that nebivolol was well tolerated in comparison to placebo and was not associated with adverse changes in blood glucose levels. Nebivolol is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension.

"Next-generation beta blockers, such as nebivolol, represent a step forward in the treatment of hypertension," said Robert J. Weiss, M.D., Director Cardiovascular Research, Maine Clinical Research. "As we saw in the study, nebivolol demonstrated efficacy with a low incidence of side effects typical of traditional beta blockers, such as fatigue, erectile dysfunction, and depression. In addition, there were no clinically significant changes in glucose levels, which makes nebivolol useful in patients with certain metabolic disorders."

In the double-blind, placebo-controlled study, a total of 909 patients were randomized to receive placebo (81 patients) or nebivolol (828 patients) dosed at 1.25mg, 2.5mg, 5mg, 10mg, 20mg or 40mg once daily for up to 12 weeks. The 40mg dose was included to study safety only. The study concluded that nebivolol, at doses of 1.25mg to 20mg once daily, significantly reduced both trough sitting diastolic and systolic blood pressure. Additionally, the study demonstrated that nebivolol was well tolerated by comparison to placebo treatment. Headache was the most common treatment-related adverse event experienced by 7.1% of the pooled nebivolol-treated patients (dosages of 1.25mg to 40mg once daily) and 7.4% of the placebo-treated patients. Of note, in the pooled nebivolol group, the incidence of AEs commonly associated with traditional beta blocker use, including fatigue (3.6% vs. 2.5% with placebo), erectile dysfunction (0.2%), and depression (0.2%) was low. Moreover, nebivolol was not associated with adverse changes in blood glucose values.

"The publication of nebivolol's first U.S. clinical trial further reinforces its longstanding use in patients worldwide," said Neil Shusterman, M.D., Senior Vice President, Clinical Development, Forest Research Institute. "The majority of Americans afflicted with this disease are still not controlled, so clearly there is a need for more treatment options. This study showed that nebivolol significantly lowered blood pressure in patients with mild-to-moderate hypertension and we anticipate it will be an important therapy for physicians."

About Hypertension

Hypertension, also known as high blood pressure, affects approximately 72 million people in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range. If left untreated, hypertension can eventually damage important organs such as the heart, brain, eyes or kidneys. High blood pressure greatly increases the risk of certain health problems such as stroke, heart attack, and kidney failure.

About Nebivolol

Nebivolol is a selective beta 1-blocker with vasodilating properties and is already approved and successfully marketed for the treatment of hypertension in more than 50 countries outside of North America.

About Forest Laboratories and Its Products

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R) * (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

* Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007, and on Form 10-Q for the period ended June 30, 2007.

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
(Date:12/1/2015)... , December 1, 2015 ... market research report "Nucleic Acid Labeling Market by Product ... Translation, Random Primer, In Vitro Transcription, Reverse Transcription, End ... by MarketsandMarkets, The global market is expected to reach ... in 2015, growing at a CAGR of 8.65%. ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... Spine, Sports & Orthopedic Rehabilitation P.C.went to NASDAQ to educate the personnel on ... specific traction therapy for the spine, a nonsurgical procedure. The benefits come from ...
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing ... Jar, a container patent that allows for easier packing and organizing of items into ... worth $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing ...
(Date:12/1/2015)... ... ... Royal River Natural Foods — a locally-owned, independent natural health store in Freeport, ... supplement creatine, along with resistance training for a year, had more new bone at ... is part of the December 2015 issue of Natural Insights for Well Being®, which ...
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... coalition of obesity groups has filed a discrimination claim against the U.S. Department of ... coverage in their Affordable Care Act (ACA) plans are breaking the clause in the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Califia Farms ... announced that its iconic bottle has won top honors in Beverage World Magazine’s Global ... Company also announced that it has been selected as a 2015 U.S.A. Taste Champion ...
Breaking Medicine News(10 mins):